Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration

被引:0
作者
Milena M. McLaughlin
Inela Masic
Lana Gerzenshtein
机构
[1] Midwestern University,Department of Pharmacy Practice, Chicago College of Pharmacy
[2] Northwestern Memorial Hospital,undefined
来源
International Journal of Clinical Pharmacy | 2017年 / 39卷
关键词
Continuous veno-vous hemofiltration; HIV; Nucleoside reverse transcriptase inhibitor; Pharmacokinetics; NRTIs;
D O I
暂无
中图分类号
学科分类号
摘要
Background Unpredictable drug concentrations may lead to suboptimal exposure to nucleoside reverse transcriptase inhibitors (NRTIs) due to inadequate doses administered during continuous veno-venous hemofiltration (CVVH), which in turn may lead to decreased antiretroviral efficacy and possibly further HIV disease progression. Objective To compare administered doses of NRTIs to calculated doses of NRTIs to evaluate if patients were expected to have a favorable pharmacokinetic exposure profile while receiving CVVH. Methods The NRTI dose was compared to a table of recommendations based on a mathematical formula that estimates the amount of drug expected to be removed during CVVH. Results Twelve patients were on 27 NRTIs. Eleven (41%) NRTI doses were expected to provide a favorable pharmacokinetic profile based on pharmacokinetic mathematical calculations. Conclusion The majority of NRTIs were potentially not optimally dosed based on proposed pharmacokinetic calculations.
引用
收藏
页码:37 / 40
页数:3
相关论文
共 45 条
  • [1] Calza L(2012)Renal toxicity associated with antiretroviral therapy HIV Clin Trials 13 189-211
  • [2] Uchino S(2007)Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators Intensive Care Med 33 1563-1570
  • [3] Bellomo R(1997)Continuous hemofiltration in the treatment of acute renal failure N Engl J Med 336 1303-1309
  • [4] Morimatsu H(2005)Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Clin Infect Dis 40 1559-1585
  • [5] Morgera S(2009)Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice J Antimicrob Chemother 64 109-117
  • [6] Schetz M(2002)Concentration-controlled compared with conventional antiretroviral therapy for HIV infection AIDS 16 551-560
  • [7] Tan I(2008)Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment Clin Pharmacokinet 47 153-172
  • [8] Forni LG(2015)Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration Clin Drug Investig 35 275-280
  • [9] Hilton PJ(1998)Drug dosing adjustments during continuous renal replacement therapies Kidney Int Suppl 66 S165-S168
  • [10] Gupta SK(2015)Acute kidney injury in patients with human immunodeficiency virus infection Indian J Nephrol 25 86-90